1. Germany Stocks

  2. •

    Health technology

  3. •

    Biotechnology
BRAIN Biotech AG

BRAIN Biotech AG

2.78
EUR
+0.03
(+1.09%)
-0.64EPS
63.79MMarket Cap
Jan 14Next Earn
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.64
1.51
1.46
1.5
2.14
2.05
1.92
2.27
2.53
2.51
2.29
2.1
Basic EPS, GAAP
-0.44
-0.97
-0.58
-0.44
-0.61
-0.52
-0.25
-0.3
-0.38
-0.51
-0.54
-0.64
Free Cash Flow per Basic Share
-0.37
-0.63
-0.41
-0.37
-0.55
-0.41
-0.26
-0.35
-0.31
-0.24
-0.5
-0.27
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.42
1.63
2.61
1.3
0.85
1.05
1.78
1.36
1
0.58
0.08
-0.33
Tangible Book Value per Share
-0.2
1.15
2.22
0.25
-0.03
0.38
1.16
0.59
0.3
-0.07
-0.49
-0.33
Basic Weighted Avg Shares
13
15
16
18
18
19
20
22
22
22
22
22
Sales/Revenue/Turnover
21
23
24
27
39
38
38
50
55
55
50
46
Operating Margin (%)
-22.72
-61.32
-39.21
-34.73
-14.32
-21.05
-19.67
-13.61
-10.77
-16.49
-14.89
-17.71
Depreciation Expense
1
1
2
3
5
4
4
4
5
5
5
5
Net Income, GAAP
-6
-15
-10
-8
-11
-10
-5
-7
-8
-11
-12
-14
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-27.04
-64.46
-39.85
-29.27
-28.79
-25.33
-12.95
-13.31
-14.96
-20.32
-23.48
-30.41
Working Capital
7
22
45
30
16
21
28
9
8
21
7
5
LT Debt
14
6
8
25
23
27
- -
- -
- -
4
- -
- -
Total Equity
6
27
47
28
20
26
42
34
23
14
2
-7
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-91.44
-26.01
-22.39
-57.15
-53.65
-16.69
-19.26
-32.21
-64.71
-162.43
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
ST Debt
- -
5
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
55
54
64

Working Capital

EUR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'26
Total Current Assets
26
23
20
Cash, Cash Equivalents & STI
- -
5
- -
Accounts Receivable, Net
- -
7
- -
Inventories
- -
9
- -
Total Current Liabilities
18
16
15
Payables & Accruals
- -
- -
- -
ST Debt
- -
5
- -
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
28.7%
-23.47%
-86.74%
Free Cash Flow
18.45%
17.26%
104.05%
Net Income, GAAP
18.18%
9.89%
5.53%
Sales/Revenue/Turnover
9.9%
6.29%
-8.66%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13
14
13
14
55
2025
13
12
13
11
50
2026
12
11
11
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.09
-0.12
-0.18
-0.51
2025
-0.18
-0.14
-0.03
-0.18
-0.54
2026
-0.13
-0.16
-0.16
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Sven K. Weber
Full Time Employees
281
Sector
Health technology
Industry
Biotechnology
Address
Darmstädter Strasse 34-36 Zwingenberg HE Germany 64673
IPO Date
Feb 9, 2016
Website
brain-biotech.de
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
BRAIN Biotech AG BRAIN Biotech AG is a leading European provider of integrated bio-based solutions and products in industrial biotechnology, focusing on the development and production of specialty enzymes, proteins, microbial production strains, and bioprocesses for applications in nutrition, health and life sciences, and environmental sectors. The company operates through two main segments, BRAINBiocatalysts, which encompasses the products business and manufacturing services including specialty enzymes, microorganisms, and bioactive natural ingredients for foodstuffs, animal feed, cosmetics, medical products, chemical processes, waste disposal, and energy production; and BRAINBioIncubator, which develops high-value proprietary R&D projects such as the CRISPR-Cas gene editing technology platform. Founded in 1993 and headquartered in Zwingenberg, Germany, BRAIN Biotech AG maintains production sites across continental Europe, the United Kingdom, and the United States, serving industrial partners through contract research, fermentation services, enzyme technology, strain development, bioprocess scale-up, and licensing of technologies. Recent developments include the October 2024 signing of an exclusive pharmaceutical licensing agreement with Akribion Therapeutics GmbH for its G-dase E CRISPR-Cas nuclease, potentially yielding up to EUR 92.3 million in milestones plus royalties while retaining non-pharma rights; the full acquisition and consolidation of Breatec B.V. in the Netherlands; the merger of AnalytiCon Discovery GmbH into the parent company to streamline group structure; and the full buyout of Biocatalysts Ltd. in the UK, marking 30 years of the company and 40 years of that subsidiary.